- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00136643
Safety, Tolerance and Acceptability Trial of the Invisible Condom® in Healthy Women
A Phase I/II Randomized, Double-Blind, Placebo-Controlled Study of the Safety, Tolerance and Acceptability of a Vaginal Gel Containing Sodium Lauryl Sulfate (Invisible Condom®) in Healthy Female Subjects
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Objectives: The objectives of this Phase I/II clinical trial are to evaluate the safety, tolerance and acceptability of a gel formulation containing sodium lauryl sulfate (SLS) (compared to gel alone and placebo) when applied intravaginally in healthy volunteers.
Design: In part A of the protocol, three groups: gel alone, gel plus SLS, and placebo will be tested for safety, tolerance and acceptability when applied intravaginally once, twice or three times daily for 14 days in 252 healthy subjects. The volunteers will be divided as follow: 36 sexually abstinent healthy subjects (12 per group) will apply the gel, gel plus SLS or the placebo once daily for 14 days; 72 sexually active healthy subjects (24 per group) will apply the gel, gel plus SLS or the placebo once daily for 14 days; 72 sexually active healthy subjects (24 per group) will apply the gel, gel plus SLS or the placebo twice daily for 14 days and 72 sexually active healthy subjects (24 per group) will apply the gel, gel plus SLS or the placebo three times daily for 14 days. The gel will be applied between menses. For the sexually active group, the gel should be applied less than 1 hour before sexual intercourse, if planned. Subjects will have vaginal intercourse a minimum of 4 times in a 2-week period of gel application.
In part B of the protocol, the extended safety of the gel alone, gel plus SLS and placebo will be studied when applied intravaginally twice daily for 8 weeks in sexually active healthy subjects. In this part B (actually represents Phase II of the trial), 80 healthy sexually active subjects for the gel alone group and 80 subjects for the gel + SLS group and 40 subjects for the placebo group, will be studied. The part B involves the participation of a total of 200 subjects. Subjects will have vaginal intercourse a minimum of 4 times in a 2-week period of gel application. The gel will be applied between menses. The gel should be applied less than 1 hour before sexual intercourse, if planned, but no more than twice a day.
Study Type
Enrollment
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Locations
-
-
-
Yaoundé, Cameroon
- Laboratoire de Santé Hygiène Mobile
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Sign an informed consent
- Healthy female subjects aged between 18 to 49. Healthy female subjects are defined as individuals who are free from clinically significant illness or disease as determined by their medical history, physical examination and laboratory tests.
- Normal physical and gynecological examinations
- Normal colposcopic examination
- Have regular menstrual cycle with 21-40 days between menses
- HIV-negative subjects and at low risk of acquiring HIV
- At low risk of getting STIs (i.e. sexually abstinent or having history of protected sexual intercourse or having a stable sexual partner). Sexual intercourse is defined here as vaginal penetration. Stable sexual partner is defined as the same sexual partner for the length of the study.
- Agreeing to abstain from sexual intercourse from screening to the end of the study (for sexually abstinent subjects).
- Agreeing to have sexual intercourse a minimum of 4 times for each period of two weeks of gel application (for sexually active subjects)
Exclusion Criteria:
- Clinically significant abnormal physical and/or gynecological examination
- Clinically significant abnormal laboratory findings
- Allergy to applicator material (polyethylene) or to gel polymer (polyoxyethylene-polyoxypropylene) or to latex
- Participation in any investigational study involving drugs, vaccines or microbicides in the last 30 days
- History of toxic shock syndrome
- HIV infection
- Bacterial vaginosis or Candida or Trichomonas vaginitis at time of screening
- STIs (gonorrhea, chlamydia, syphilis, genital herpes, chancroid) at time of screening
- Breakthrough menstrual bleeding, or vaginal bleeding during or following sexual intercourse, in the last 3 months
- Intravenous (IV) drug use except for medical reasons in the last year
- Pregnant at enrolment or breast-feeding
- Having received antibiotics in the last 14 days
- Subjects considered as unreliable or unable to understand or follow the study protocol directions
- Use of an intrauterine device
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
---|
Safety and tolerance outcomes: Subjective assessment; Objective assessment
|
Secondary Outcome Measures
Outcome Measure |
---|
Acceptability assessment
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Michel G. Bergeron, MD, FRCPC, Prof. and Director of Infectious Diseases Research Center, Laval University
Study record dates
Study Major Dates
Study Start
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- CRI-INV.06
- FRN: 67531
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on HIV Infections
-
University of MinnesotaWithdrawnHIV Infections | HIV/AIDS | Hiv | AIDS | Aids/Hiv Problem | AIDS and InfectionsUnited States
-
University of California, San DiegoUniversity of California, Los Angeles; University of Southern California; California... and other collaboratorsCompleted
-
Gérond'ifRecruiting
-
University of California, DavisCompleted
-
University of California, San DiegoNational Center for Complementary and Integrative Health (NCCIH)CompletedHIV PositiveUnited States
-
University of ChicagoUniversity of Athens; National Development and Research Institutes, Inc.Completed
-
HIV Prevention Trials NetworkNational Institute on Drug Abuse (NIDA); National Institute of Allergy and...CompletedHIV PositiveIndonesia, Ukraine, Vietnam
-
University of ZimbabweCompleted
-
Florida International UniversityCompleted
-
Boston Children's HospitalNational Institute on Minority Health and Health Disparities (NIMHD)Completed
Clinical Trials on Invisible Condom®
-
Sagami Rubber Industries Co., Ltd.Essential Access HealthCompletedContraception | Prevention of Sexually Transmitted InfectionsUnited States
-
Prof Mags BeksinskaCompletedFunctional PerformanceSouth Africa
-
Ohio State UniversityUniversity of North Carolina, Chapel Hill; Ministry of Health, VietnamCompleted
-
Prof Mags BeksinskaCompletedPregnancy PreventionSouth Africa
-
Sagami Rubber Industries Co., Ltd.Essential Access HealthCompletedContraception | Prevention of Sexually Transmitted InfectionsUnited States
-
Okamoto Industries, Inc.NAMSAActive, not recruitingPerformance of Synthetic Polyurethane Male CondomUnited States
-
Karex Industries Sdn. Bhd.Essential Access Health; Match Research; Sigma3 Services SARLRecruitingSexually Transmitted DiseasesUnited States, South Africa
-
Mamms Institute of Fistula and Womens HealthInternational Centre for Diarrhoeal Disease Research, BangladeshCompletedPost Partum Hemorrhage
-
HydroGlyde Coatings, LLCEssential Access HealthEnrolling by invitationCondom UsersUnited States
-
Reckitt Benckiser Healthcare (UK) LimitedNovotech (Australia) Pty LimitedCompletedControl of Pregnancy | Prevention of Sexually Transmitted InfectionsThailand